Navelbine (Vinorelbine Tartrate)

Navelbine (vinorelbine tartrate) is used in oncology to target rapidly dividing cancer cells in specific solid tumours.

• Non‑small cell lung cancer: improves disease control and may extend survival when used in combination chemotherapy.
• Metastatic breast cancer: reduces tumor burden and delays progression as part of multi‑agent regimens.
• Other solid tumours (off‑label): may be incorporated into specialist‑guided combination protocols for selected patients.

• Vinorelbine tartrate binds to tubulin at the plus end of microtubules, preventing polymerisation and thereby disrupting the mitotic spindle. This inhibition arrests cells in the M‑phase of the cell cycle, leading to apoptosis of rapidly proliferating tumour cells. The drug’s activity is independent of DNA synthesis and is selective for dividing cells. The effect is dose‑dependent and is enhanced when combined with agents that target other phases of the cell cycle.

Vinorelbine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea and vomiting
• Fatigue
• Constipation
• Neutropenia

Serious or Rare Side Effects

• Febrile neutropenia (severe infection with low white cells)
• Pulmonary toxicity (interstitial pneumonitis)

When prescribing Navelbine, clinicians should observe several precautionary measures to minimise risk.

• Monitor blood counts: perform regular complete blood count tests to detect neutropenia or anemia.
• Assess liver function: adjust use in patients with hepatic impairment.
• Evaluate for pre‑existing neuropathy: vinorelbine may exacerbate nerve damage.
• Avoid in severe bone‑marrow suppression: contraindicated in patients with critically low blood cell levels.
• Use effective contraception: pregnancy category unknown; advise reliable birth control during treatment and for a defined period after.
• Store at ambient temperature: keep capsules in the original container, protect from moisture and light.

Vinorelbine can interact with other medicines, influencing its efficacy or toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase vinorelbine exposure.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect.

Moderate Interactions (Monitor Closely)

• Other myelosuppressive agents (e.g., cyclophosphamide, paclitaxel): additive bone‑marrow toxicity.
• Anticoagulants (e.g., warfarin): potential for enhanced bleeding risk.
• Drugs that prolong QT interval (e.g., quinidine): may increase cardiac arrhythmia risk.